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THIS ISSUE’S AUTHORS 
ROBERT K. BROONER, Ph.D., is profes­
sor of medical psychology at Johns Hopkins 
University (JHU) in Baltimore, and he 
directs JHU’s Addiction Treatment Services 
at Bayview Medical Center. He has worked 
in the field of behavioral science and sub­
stance abuse for 20 years and has published 
extensively in research areas including alco­
holism, injection drug abuse, multiple 
diagnoses in drug abusers, and the use of 
incentives in drug abuse treatment. 
TONY P. GEORGE, M.D., is assistant pro­
fessor of psychiatry at Yale University School 
of Medicine and director of the Dual 
Diagnosis and Smoking Research Program 
at the Connecticut Mental Health Center. 
His research has focused on the effects of 
abused drugs on clinical and cognitive 
function in patients with chronic mental 
illness. 
T. RON  JACKSON, M.S.W., is executive 
director of Evergreen Treatment Services 
and affiliate associate professor in the School 
of Social Work, University of Washington, 
Seattle. He has worked as a clinician, admin­
istrator, researcher, and educator in addic­
tion treatment, specializing in opiate 
dependence, since 1972. 
MICHAEL KIDORF, Ph.D., is associate 
professor in psychiatry and behavioral sci­
ences at JHU, as well as associate director 
of JHU’s Addiction Treatment Services at 
Bayview Medical Center. His research inter­
ests and publications include the subjects 
of methadone maintenance therapy, psy­
chiatric and substance use cormorbidity, 
and contingent rewards in outpatient drug 
abuse treatment programs. 
THOMAS R. KOSTEN, M.D., is professor 
of psychiatry at Yale University School of 
Medicine and chief of psychiatry for the 
VA Connecticut Healthcare System. His 
major research area has been psy­
chopharmacology of medications used to 
treat cocaine abuse. Some of his studies 
focus on psychiatric disorders in substance 
abusers and on the neurobiology of sub­
stance dependence. 
CARMEN L. MASSON, Ph.D., assistant 
adjunct professor at the University of 
California, San Francisco, has focused her 
research on behavioral interventions 
designed to reduce risky behaviors linked 
with HIV and other infectious diseases 
among drug-dependent individuals. Her 
research interests also include the role of 
cofactors such as homelessness and psy­
chiatric conditions in the ability of drug 
abusers to engage in preventive health 
behaviors. 
OLGA V. PARKER, Ph.D., is clinical direc­
tor at CODA, the largest alcohol and drug 
treatment agency in Portland, Oregon. 
Dr. Parker has worked in substance abuse 
treatment for 17 years and as a psy­
chotherapist for more than 20 years. 
DAVID C. PERLMAN, M.D., is professor 
of medicine at Albert Einstein College of 
Medicine and director of the AIDS inpa­
tient unit at Beth Israel Medical Center 
in New York. His research interests focus 
on the infectious complications of HIV 
and substance abuse, and on strategies to 
deliver care to drug users. 
JAMES L. SORENSEN, Ph.D., is adjunct 
professor of psychiatry at the University 
of California, San Francisco (UCSF), and 
a co-principal investigator for the UCSF 
Treatment Research Center. Over the past 
20 years, he has developed and evaluated 
a community network approach to drug 
abuse treatment, assessed the efficacy of 
family therapy for methadone mainte­
nance patients, and tested the efficacy 
of small-group HIV education in three 
drug abuse treatment modalities. 
ANN S. UHLER, M.A., is executive direc­
tor of CODA, Inc., in Portland, Oregon. 
Ms. Uhler has more than 25 years’ expe­
rience in the substance abuse field, and 
she is a certified practitioner of psycho­
drama, sociometry, and group psy­
chotherapy. Ms. Uhler is a provider rep­
resentative on NIDA’s National Drug 
Abuse Treatment Clinical Trials Network. 
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JANELLE BLAKE, CAC III, is a clinician 
with Denver’s Addiction Research and 
Treatment Services who specializes in treat­
ment of HIV-infected substance-abusing 
patients. 
TOM BREWSTER, M.S.W., is executive 
director of Addiction Research and 
Treatment Services, an agency providing 
services to approximately 1,500 clients. 
He is associate professor in psychiatry, 
University of Colorado School of Medicine, 
and has more than 30 years’ experience in 
substance abuse treatment and research 
activities. 
R. LORRAINE COLLINS, Ph.D., is senior 
research scientist, Research Institute on 
Addictions, University at Buffalo, State 
University of New York. Her research inter­
ests include prevention and treatment of 
addictions, cognitive factors in alcohol use 
and abuse, alcohol and violence, and psy­
chosocial issues as they relate to substance 
use and misuse. 
WILLIAM CORNELY, M.H.S., is vice pres­
ident of research and development at Fresh 
Start, Inc., in Philadelphia. Fresh Start is 
a residential, comprehensive, addiction­56 • SCIENCE & PRACTICE PERSPECTIVES—JULY 2002 
recovery care-management organization 
that participates in NIDA’s Clinical Trials 
Network. Mr. Cornely also has served as 
clinical director at various inpatient and 
intensive outpatient treatment programs 
in the Philadelphia area. 
MARLA CORWIN, L.C.S.W., CAC III, is 
clinical services coordinator for Addiction 
Research and Treatment Services in Denver, 
with extensive experience in direct clini­
cal care for adults and working with the 
specialty populations of HIV-infected sub­
stance abusers and patients involved in 
the child welfare system 
ERIC ENNIS, L.C.S.W., CAC III, is instruc­
tor of psychiatry and the director of adult 
outpatient services for Addiction Research 
and Treatment Services in Denver. Mr. 
Ennis oversees five community-based clinic 
sites for ARTS in the Denver Metro area, 
including specialized programs for women, 
HIV-infected substance abusers, offend­
ers, and opioid-dependent patients. 
OLIVIA ESTEP, B.S.N., R.N., CAC III, is 
clinic coordinator, outpatient women’s 
treatment services for Addiction Research 
and Treatment Services in Denver. The 
program has innovative components and 
enhancements designed to attract women 
with substance abuse problems and retain 
them in treatment. 
CHRIS FARENTINOS, M.D., is clinical 
director and co-owner of ChangePoint 
Inc., which participates in two ongoing 
research projects: NIDA’s Clinical Trials 
Network and the Practice-Research 
Collaboratives funded by the Center 
for Substance Abuse Treatment. Dr. 
Farentinos has been in the alcohol and 
drug abuse field for 13 years and was 
recently appointed as adjunct faculty for 
the Oregon Health Sciences University 
School of Public Health and Preventive 
Medicine. 
CHRISTINE GRELLA, Ph.D., is associ­
ate research psychologist at the UCLA 
Integrated Substance Abuse Programs, 
Neuropsychiatric Institute. Dr. Grella has 
conducted field-based treatment outcome 
studies within both mental health and 
substance abuse treatment settings, using 
both experimental and naturalistic research 
designs. Her research has focused on treat­
ment processes and outcomes, with an 
emphasis on special populations. 
DARIA LESLEA, L.P.N., CAC II, is nurse, 
clinician, and clinical supervisor at the 
Addiction Research and Treatment Services 
Outpatient Clinic in Denver. She works 
with opioid-dependent patients and is spe­
cial liaison for local social services depart­
ments. 
SCOTT POWERS, M.S.W., CAC III, is clinic 
coordinator for the Addiction Research 
and Treatment Services CrossPoint Program 
in Denver, a specialized outpatient clinic 
for State and Federal offenders with sub­
stance abuse problems. 
DOUGLAS ZIEDONIS, M.D., M.P.H., is 
director of the Division of Addiction 
Psychiatry and associate professor with 
tenure at the Robert Wood Johnson Medical 
School, University of Medicine and Dentis­
try of New Jersey. Dr. Ziedonis is a prin­
cipal investigator for the Mercer Trenton 
Addiction Science Center, part of the 
Delaware Valley Node of NIDA’s Clinical 
Trials Network. 